A New Weak Spot in Prostate Cancer: Disarming the Androgen Signal by Targeting PTGES3

/in , /by

A new study shows, published on Nature, that a little-known protein called PTGES3 helps prostate cancer cells keep using male hormone signals to grow, even when treatments are trying to shut those signals down. Blocking this helper protein cut off the cancer’s fuel supply in lab tests and slowed tumors in mice, pointing to a […]

Read more

GenSci143: A Dual-Target ADC Emerging for Metastatic Prostate Cancer

/in , , /by

GenSci143 (aka GenSci-143) is a bispecific antibody-drug conjugate under development for metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors. The construct targets B7-H3 (CD276) and PSMA simultaneously with a bispecific antibody, coupled via a stable, cleavable linker to a topoisomerase I inhibitor payload, aiming to improve tumor cell killing and bystander effects across heterogeneous […]

Read more

Low‑Dose Naltrexone for ADT‑Related Fatigue in Prostate Cancer

/in , , , , /by

A new trial will test whether nightly low‑dose naltrexone (3 mg) reduces fatigue in men with prostate cancer receiving androgen‑deprivation therapy (ADT), while concurrently profiling mitochondrial, inflammatory, and oxidative stress pathways that may drive cancer‑related fatigue in this setting. The single‑arm University of Arkansas study plans to enroll 60 men over 30 months, using FACIT‑F […]

Read more

177Lu-PSMA-617 (Pluvicto) Combo With Sipulecel-T in Phase 1 Trial

/in , , /by

City of Hope Medical Center, in collaboration with the National Cancer Institute, is initiating a randomized phase 1 study in metastatic castration‑resistant prostate cancer (mCRPC) that compares lutetium Lu 177 vipivotide tetraxetan (177Lu‑PSMA‑617 or Pluvicto) alone versus the same radioligand combined with sipuleucel‑T, with the primary goal of quantifying the induced anti‑tumor immune response alongside […]

Read more

News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule

/in , /by

A novel dual payload peptide drug conjugate technology, known as the pre|CISION® platform, represents an advance in oncology by delivering two complementary anticancer therapies from a single molecule. This approach leverages the fibroblast activation protein (FAP), which is selectively present in the tumor microenvironment, especially in advanced prostate cancer such as castration-resistant prostate cancer (CRPC). […]

Read more

Helicon Degraders Show a New Path in Prostate Cancer Therapy

/in /by

In one of the most compelling advances for prostate cancer biology in recent years, a novel peptide-based degrader has achieved potent, selective elimination of the transcription factor ERG, an oncogenic driver long considered unreachable by medicinal chemistry. The discovery has upended conventional views on druggability in TMPRSS2–ERG fusion–positive prostate cancers, which comprise nearly half of […]

Read more

UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer

/in , , , /by

A first-in-human clinical trial conducted at The University of Texas MD Anderson Cancer Center has revealed encouraging early results for HLD-0915, a new oral therapy designed for patients with metastatic castration-resistant prostate cancer (mCRPC). The findings, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, indicate that HLD-0915 is well tolerated and […]

Read more

Final OS Data from EMBARK Phase 3 Trial: Enzalutamide With ADT for Men at Risk of BRPC

/in , , /by

Data from the phase 3 EMBARK trial, combining enzalutamide with standard hormone therapy, recently published in The New England Journal of Medicine and presented at the 2025 European Society for Medical Oncology (ESMO) Congress, reveal that this combination reduces the risk of death by more than 40% over eight years compared to hormone therapy alone. […]

Read more